Tag Archives: Morphotek

February, 2016

December, 2015

  • 7 December

    Morphotek Announces Early-Stage Results from its Rheumatoid Arthritis Study

    EXTON, Pa., Dec. 7, 2015 /PRNewswire/ — Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending, placebo-controlled, Phase 1 trial evaluating the safety and tolerability of its investigational, anti-GM-CSF, monoclonal antibody, MORAb-022 in healthy subjects (n=26) and mild-to-moderate Rheumatoid Arthritis (RA) patients (n=25). In this …

November, 2015